Igc Pharma (IGC) revenue and earnings history
Igc Pharma reported revenue of $1.27M for fiscal 2025 (year ended Mar 31, 2025), −5.5% on the year before, and net income of −$7.12M.
Over 14 years, from fiscal 2011 to fiscal 2025, revenue grew at a compound rate of −8.0% a year.
Revenue and net income, 15 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Mar 31, 2025 | $1.27M−5.5% | −$7.45M | −$7.12M | −$4.79M | $112K | −$4.91M | $4.3M | — | — | $405K | $134K | 10-K |
| 2024ended Mar 31, 2024 |
The latest quarter, insider trades and fund moves: Igc Pharma (IGC) on OQRO.
Common questions
What was Igc Pharma's revenue in fiscal 2025?
$1.27M for the year ended Mar 31, 2025, as reported in its 10-K filed Jun 27, 2025. That is −5.5% on fiscal 2024 ($1.34M).
How fast has Igc Pharma's revenue grown?
From $4.07M in fiscal 2011 to $1.27M in fiscal 2025: a compound annual growth rate of −8.0% over 14 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Igc Pharma been profitable?
Where these figures come from
The SEC’s companyfacts data: every figure Igc Pharma tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
